Expert consensus on drug treatment of chronic subdural hematoma

Abstract Chronic subdural hematoma (CSDH) is a chronic space-occupying lesion formed by blood accumulation between arachnoid and dura mater, which is usually formed in the third week after traumatic brain injury. Surgical treatment is usually the first choice for patients with CSDH having a signific...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jianning Zhang, Chinese Society of Neurosurgery, Chinese Medical Association, Chinese Neurosurgical Critical Care Specialist Council, Collaborational Group of Chinese Neurosurgical Translational and Evidence-based Medicine
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Surgery RD1-811 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/c9a914fd0cd84056a78c01884c6499fc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c9a914fd0cd84056a78c01884c6499fc
record_format	dspace
spelling	oai:doaj.org-article:c9a914fd0cd84056a78c01884c6499fc2021-11-28T12:22:29ZExpert consensus on drug treatment of chronic subdural hematoma10.1186/s41016-021-00263-z2057-4967https://doaj.org/article/c9a914fd0cd84056a78c01884c6499fc2021-11-01T00:00:00Zhttps://doi.org/10.1186/s41016-021-00263-zhttps://doaj.org/toc/2057-4967Abstract Chronic subdural hematoma (CSDH) is a chronic space-occupying lesion formed by blood accumulation between arachnoid and dura mater, which is usually formed in the third week after traumatic brain injury. Surgical treatment is usually the first choice for patients with CSDH having a significant space-occupying effect. Most of the patients showed good results of surgical treatment, but still some patients had a postoperative recurrence (the recurrence rate was up to 33%). Because CSDH is often seen in the elderly, patients are weak and have many basic diseases. The risk of surgical treatment is high; serious complications and even death (the death rate is up to 32%) can often occur. The overall good prognosis rate of patients aged more than 90 years is 24%. The drug treatment can provide a safe and effective treatment for elderly patients who are weak, intolerable to surgery, or failed in surgery. Low-dose and long-term use of atorvastatin (20mg/d) is suggested for continuous treatment for at least 8 weeks, while low-dose and short-term use of dexamethasone can improve the therapeutic effect of atorvastatin on CSDH. Patients should undergo CT or MRI scanning at least one time within 2 weeks after the start of drug treatment.Jianning ZhangChinese Society of Neurosurgery, Chinese Medical Association, Chinese Neurosurgical Critical Care Specialist Council, Collaborational Group of Chinese Neurosurgical Translational and Evidence-based MedicineBMCarticleSurgeryRD1-811Neurology. Diseases of the nervous systemRC346-429ENChinese Neurosurgical Journal, Vol 7, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Surgery RD1-811 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Surgery RD1-811 Neurology. Diseases of the nervous system RC346-429 Jianning Zhang Chinese Society of Neurosurgery, Chinese Medical Association, Chinese Neurosurgical Critical Care Specialist Council, Collaborational Group of Chinese Neurosurgical Translational and Evidence-based Medicine Expert consensus on drug treatment of chronic subdural hematoma
description	Abstract Chronic subdural hematoma (CSDH) is a chronic space-occupying lesion formed by blood accumulation between arachnoid and dura mater, which is usually formed in the third week after traumatic brain injury. Surgical treatment is usually the first choice for patients with CSDH having a significant space-occupying effect. Most of the patients showed good results of surgical treatment, but still some patients had a postoperative recurrence (the recurrence rate was up to 33%). Because CSDH is often seen in the elderly, patients are weak and have many basic diseases. The risk of surgical treatment is high; serious complications and even death (the death rate is up to 32%) can often occur. The overall good prognosis rate of patients aged more than 90 years is 24%. The drug treatment can provide a safe and effective treatment for elderly patients who are weak, intolerable to surgery, or failed in surgery. Low-dose and long-term use of atorvastatin (20mg/d) is suggested for continuous treatment for at least 8 weeks, while low-dose and short-term use of dexamethasone can improve the therapeutic effect of atorvastatin on CSDH. Patients should undergo CT or MRI scanning at least one time within 2 weeks after the start of drug treatment.
format	article
author	Jianning Zhang Chinese Society of Neurosurgery, Chinese Medical Association, Chinese Neurosurgical Critical Care Specialist Council, Collaborational Group of Chinese Neurosurgical Translational and Evidence-based Medicine
author_facet	Jianning Zhang Chinese Society of Neurosurgery, Chinese Medical Association, Chinese Neurosurgical Critical Care Specialist Council, Collaborational Group of Chinese Neurosurgical Translational and Evidence-based Medicine
author_sort	Jianning Zhang
title	Expert consensus on drug treatment of chronic subdural hematoma
title_short	Expert consensus on drug treatment of chronic subdural hematoma
title_full	Expert consensus on drug treatment of chronic subdural hematoma
title_fullStr	Expert consensus on drug treatment of chronic subdural hematoma
title_full_unstemmed	Expert consensus on drug treatment of chronic subdural hematoma
title_sort	expert consensus on drug treatment of chronic subdural hematoma
publisher	BMC
publishDate	2021
url	https://doaj.org/article/c9a914fd0cd84056a78c01884c6499fc
work_keys_str_mv	AT jianningzhang expertconsensusondrugtreatmentofchronicsubduralhematoma AT chinesesocietyofneurosurgerychinesemedicalassociationchineseneurosurgicalcriticalcarespecialistcouncilcollaborationalgroupofchineseneurosurgicaltranslationalandevidencebasedmedicine expertconsensusondrugtreatmentofchronicsubduralhematoma
_version_	1718408042631921664

Expert consensus on drug treatment of chronic subdural hematoma

Ejemplares similares